Merck & Co.
AWARDS
NEWS
ALX Oncology will partner with pharma giant Merck to evaluate a combination of its CD47 inhibitor with Keytruda as a potential treatment for patients with Head & Neck Squamous Cell Carcinoma.
The European Society for Medical Oncology (ESMO) Virtual Congress 2020 was this weekend, with numerous companies presenting clinical trial data and updates.
The overall survival benefit of Lynparza was shared this weekend, four months after the U.S. Food and Drug Administration approved it as a treatment for prostate cancer.
Biopharma companies focused on oncology continue to release data that will be presented at the 2020 virtual meeting of the European Society of Medical Oncology.
Vaccinex, a company developing a novel approach to treat both cancer and neurodegenerative disease through the inhibition of SEMA4D, will pair its lead asset with Merck’s vaunted checkpoint inhibitor Keytruda.
Merck is making a major investment into Bothwell, Washington-based Seattle Genetics with two strategic oncology deals.
JOBS
IN THE PRESS